C-Jun-amino-terminal kinase-interacting protein 1 (JIP-1) (JIP-1)

C-Jun-amino-terminal kinase-interacting protein 1 (JIP-1), also known as Islet-brain 1 (IB1), is a scaffold protein that plays a central role in the regulation of the c-Jun N-terminal kinase (JNK) signaling pathway (UniProt Q9UQF2). It functions by assembling JNK and its upstream activators, such as MKK7 and MLK family kinases, into a functional signaling complex, thereby ensuring specific and efficient signal transduction (PubMed PMID: 9380482). JIP-1 is highly expressed in the brain and pancreatic beta cells, where it influences processes ranging from axonal transport and neuronal apoptosis to insulin secretion and glucose metabolism (PubMed PMID: 12432324). In neurodegenerative diseases like Alzheimer's and Parkinson's, JIP-1-mediated JNK activation is linked to pathological cell death and protein aggregation (PubMed PMID: 11085986). Consequently, JIP-1 has emerged as a therapeutic target, with research focusing on peptide inhibitors like Brimapitide (XG-102) that disrupt the JNK-JIP-1 interaction to provide neuroprotection (ClinicalTrials.gov NCT00614770). Despite its potential, therapeutic development faces challenges regarding the specificity of JNK inhibition and the delivery of large peptide molecules across biological membranes.

Other names

MAPK8IP1JNK-interacting protein 1Islet-brain 1IB1Mitogen-activated protein kinase 8-interacting protein 1PRKM8IP

Competitive inhibition of the JNK-binding site using peptide mimetics derived from the JIP-1 sequence to prevent JNK from phosphorylating its downstream targets (PubMed PMID: 12432324).